Hemispherx Biopharma Inc (HEB)
23 Sep 2016
* Frigate Ventures Lp reports 6.9 pct passive stake in Hemispherx Biopharma Inc as of August 31, 2016 - SEC filing Source text: (http://bit.ly/2cATyOR) Further company coverage:
* Sabby Management LLC reports 6.92 percent passive stake in Hemispherx Biopharma Inc as of August 31 - Sec Filing Source text : http://bit.ly/2bFyk25 Further company coverage:
* Hemispherx Biopharma Inc announces $5 million registered direct offering
* Received approval of its new drug application from anmat for commercial sale of rintatolimod in argentine republic
* Received approval of NDA in argentine republic for treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome
* Split will reduce number of shares of co's common stock currently outstanding from about 249 million shares to about 20.7 million shares Source text for Eikon: Further company coverage:
* Hemispherx biopharma announces financial results for the six months ended june 30, 2016
* Agreement with Avrio Biopharmaceuticals, Irvine California, to serve as additional contract manufacturer of Hemispherx's Ampligen
* Hemispherx outlines key elements of strategic growth plan and commitment to transparency
* Hemispherx updates the status of the Alferon manufacturing facility
Earnings vs. Estimates
Analyst Research Reports
Provider : S&P Capital IQ Quantitative Report
Provider : Pechala's Reports
Hemispherx Biopharma Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
Provider : New Constructs, LLC
Provider : Ford Investor Services, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.